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Abstract: Slightly after the emergence some 400 millions years ago of the first signs of adaptive
immune response, tolerogenic pathways developed in order to preserve the integrity of self from
potential autoimmune toxicity. Amongst those tolerogenic pathways, the thymus occupies a
central place both by deleting self-reactive T cells that are produced in the thymus during random
recombination of gene segments encoding the variable parts of the T-cell receptor for antigen
(TCR) (negative selection), and by generating self-antigen specific regulatory T cells (Tr). A
repertoire of neuroendocrine-related genes are transcribed by thymic stromal cells — epithelial
and ‘nurse’ cells (TEC/TNC), dendritic cells (DC) and macrophages (MF ) — in such a way that a dominant protein
precursor is expressed in the thymus environment. Oxytocin (OT) and neurokinin A (NKA) are the dominant thymic
precursors for the neurohypophysial hormone and tachykinin families, respectively. With regard to the insulin gene
family, all members are transcribed following a precise cell topography and hierarchy in the profile of gene expression:
IGF2 (TEC/TNC) > IGF1 (MF ) >> INS (medullary TEC and/or DC). This hierarchy implies that IGF-2 is more tolerated
than IGF-1, and much more than Insulin (Ins). The low level of INS transcription in the thymus also explains why Ins
displays immunogenic properties, as well as the significant prevalence (±40%) of anti-Ins autoantibodies in the general
population. Ins administration failed in providing tolerance or protection toward islet ß cells in type 1 diabetes (T1D). In
contrast, the presentation of IGF-2 B11-25, the homologous sequence of Ins B9-23, to peripheral blood mononuclear cells
(PBMC) isolated from DQ8+ T1D adolescents significantly increases IL-10 secretion and IL10 expression. Given the
potent regulatory/suppressive properties of IL-10 on the autoimmune response toward islet ß cells, these data support that
IGF-2 derived sequences constitute a strong basis for the development of an antigen-specific driven tolerogenic approach
for T1D prevention and/or cure.
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A BROAD OVERVIEW OF THYMUS PHYSIOLOGY
The physiology of the immune system is characterized by
three fundamental properties: response diversity, induction
of memory cells, and inability to aggress host components
(self-tolerance). The thymus is the very unique lymphoid
structure specialized both in the stochastic generation of
diversity of T cell antigen receptors (TCR) and in the
establishment of central self-tolerance. This latter results
from the clonal deletion of self-reactive T cells emerging
during intrathymic random recombination of variable TCR
segment genes [1], as well as the generation of self-antigen
specific regulatory T cells (Tr) [2,3]. Even antigen-
dependent B cell tolerance is most often due to absence of
thymus-derived T-cell help [4].
The dual physiological role of the thymus in T cell
development (thymopoiesis) and self-tolerance induction is
ensured by the cellular components of the thymic stroma.
Thymic epithelial cells (TEC) represent the major cell
population (± 80%) of the thymic stroma and are distributed
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in three regions: subcapsular cortex, inner cortex and
medulla. During embryonic development, TEC derive from
epithelial stem cells that have been recently identified in the
primitive endoderm [5,6]. In the outer cortex, thymic “nurse”
cells (TNC) are large TEC that engulf up to 50 thymocytes
(immature T cells) inside leaflets of TNC plasma membrane
[7]. Derived from bone marrow, thymic dendritic cells (DC)
are located at the cortico-medullary junction, while
macrophages are distributed throughout the thymic stroma
without any precise topography. From primitive
hematopoietic sites, T-cell progenitors migrate into the
thymus, proliferate in the outer cortex, and pursue their
differentiation program from cortex to medulla at the contact
of thymic stromal cells. Presentation of self-antigens to
randomly rearranged TCR constitutes one major component
of the multiple signaling pathways between thymic stromal
cells and pre-T cells. This process responsible for the
deletion of self-reactive T cells is very powerful since only
1-2% of pre-T cells will leave the thymus in a state of
competence against non self and tolerance to self [8].
To explain this dual role of the thymus, the affinity-
avidity model [9] proposes that clonal deletion is the fate of
T cells bearing a TCR with high affinity for self-antigens
presented at high density by thymic major histocompatibility
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complex (MHC) molecules. T cells with a low-affinity TCR
or confronted with self-antigens at too low density will die
by “neglect”, while those with intermediate affinity/avidity
will be selected for further development. It is, however,
important to note that, given the rather low affinity of a
given TCR for its specific antigen (KD around 10
-7 M), the
biological meaning of lower affinities may be questioned.
A significant advance in our understanding of thymic
physiology was gained with the demonstration that a
repertoire of neuroendocrine-related, as well as peripheral
antigen-encoding genes, are transcribed in thymic stromal
cells [10-15]. Based on the intrathymic transcription of
neurohypophysial and tachykinin genes, another model was
proposed to explain at the molecular level the paradox of
thymus physiology. Oxytocin (OT) and neurokinin A (NKA)
are expressed in TEC/TNC as the dominant members of the
neurohypophysial and tachykinin families, respectively
[16,17]. Thymic OT and NKA precursors engage two
distinct types of interactions with developing T cells. First,
they are the source of ligands that bind with high affinity to
neuroendocrine receptors expressed by pre-T cells. In this
type of cryptocrine signaling [18,19], those ligands are not
secreted but targeted to the outer surface of thymic stromal
cell plasma membrane. Secondly, the same precursors
undergo another type of processing and deliver self-antigens
that are presented by the thymic MHC machinery [20,21].
Thus, in the thymus, a confrontation occurs throughout life
between previously established neuroendocrine principles
and a recently evolved system characterized by stochastic
generation of its response diversity. According to this model,
the intrathymic presentation of neuroendocrine self is
responsible for the establishment of central self-tolerance of
neuroendocrine functions [22].
THE THYMIC INSULIN-LIKE GROWTH FACTOR
AXIS
During further experimentation with this working model,
using a battery of specific polyclonal and monoclonal
antibodies, a strong immunoreactivity for insulin-like growth
factor (IGF) 2 was detected in the epithelium of human and
rat thymi [23]. Although the protein was detected in cell
bodies of human TEC primary cultures, no IGF-2 could be
detected in the incubation media. In addition, using confocal
microscopy, immunoreactive (IR) IGF-2 was evidenced at
the outer surface of cultured human TEC plasma membrane
(Achour et al., PhD Thesis, University of Liege, Faculty of
Science). IR IGF-1 was also identified in thymic stromal
cells with a thymic macrophage-like morphology and
topography. With two monoclonal antibodies directed
against distinct epitopes of insulin, we did not find any
significant immunoreactivity in human thymic lobules
although some faint insulin immunoreactivity could be
discussed in some subsets of medullary TEC. Nevertheless,
from those studies, it was clear that IGF-2 is by far the
dominant insulin-related protein first encountered by
immature T cells during their differentiation process in the
thymus [23].
Independently, another group generated transgenic mice
carrying one of three human IGF2 minigenes containing
different non-coding exons preceding the coding exons 7, 8
and 9, spaced by truncated introns [24]. Those constructs
were placed under transcriptional control of the MHC H-2Kb
promoter-enhancer. Overexpression of IGF-2 did not affect
overall body growth, but provoked a marked thymic
hyperplasia suggesting a role of IGF-2 in thymic
development by paracrine/autocrine action. By in situ
hybridization, transcripts of the IGF2 transgene were found
at high density in the thymic non-lymphoid medulla and in
scattered positive cells in the thymic cortex. Intense IR IGF-
2 staining was observed by IHC with the same distribution of
IGF2 mRNA [25]. Moreover, IGF2 overexpression in these
transgenic mice increases thymic cellularity and stimulates
the production of normal mature T cells with a slight
polarization towards the CD4+ phenotype [26].
The various components of the IGF axis have been
described in the normal human thymus. Promoters P3 and P4
are active in the control of IGF2 transcription by human
TEC. Transcripts of type 1 and 2 IGF receptor genes were
detected in human lymphoid Jurkat T cells but not in
cultured human TEC. By Northern blot analyses, genes
encoding IGF-binding protein (IGFBP)-2 to –6 (but not
IGFBP-1) are expressed in TEC with a dominance of
IGFBP-4. Lymphoid Jurkat T cells only express IGFBP-2,
but at quite high levels [27].
The functional relevance of the thymic insulin-like
growth factor axis has been investigated using murine fetal
thymic organ cultures (FTOC). In murine fetal thymic lobes,
Igf2 and Igf1 transcripts were detected in TEC and
macrophages, respectively [28]. Treatment of FTOC with an
anti-IGF-1 antibody did not affect thymopoiesis. However, T
cell differentiation at early stages (CD4-8-, double negative)
was severely inhibited when FTOC were treated with
antibodies against IGF-2, IGF type 1 receptor, and even IGF
type 2 receptor [28]. In addition, proinsulin did not affect
thymopoiesis or T cell differentiation in this FTOC model.
Such findings and the thymopoietic effects of IGF-2
overexpression in a transgenic model strongly suggest that
IGF-2, rather than IGF-1 and insulin, is an important tissue
factor for thymopoiesis.
CENTRAL SELF-TOLERANCE OF THE INSULIN
FAMILY
The members of the insulin gene family are all
transcribed in the thymic stromal cells with a precise
topography and hierarchy in their respective expression
level. As discussed above, IGF2 is transcribed by TEC in the
whole cortex and in medulla, while IGF1 is expressed by
thymic macrophages. INS is transcribed by some subsets of
medullary TEC [29], and these cells are now identified as a
unique cell type that can express “promiscuously” and
randomly a large number of tissue-specific genes with the
potential to induce the central self-tolerance of peripheral
tissue antigens [15]. Thus, immune self-tolerance of a family
that is crucial for vital aspects such as fetal development,
postnatal growth and glucose metabolism is established at
the central level through the intrathymic expression of INS,
IGF1 and IGF2.
Presentation of Neuroendocrine Self in the Thymus Drug Design Reviews - Online, 2004, Vol. 1, No. 1    39
Experimental evidence also exists that the degree of
tolerance to a given protein is closely correlated with its
intrathymic concentration [30,31]. In parallel with this
hierarchy, immune tolerance of IGF-2 is higher than IGF-1,
and much more than insulin. This is indirectly reflected by
the frequency and titer of antibodies obtained after active
immunization with the three peptides [32]. In the same line
of reasoning, the high occurrence of anti-insulin
autoantibodies in the normal population [33] could be linked
to the low level of INS expression within the human thymus.
The IGF-2 protein contains peptide sequences that have been
highly conserved throughout evolution of the insulin family.
Because of this close homology, thymic IGF-2 would be a
good candidate for inducing central immune self-tolerance of
the whole insulin family although the tolerance to insulin per
se would be weaker. This again might explain why B- and T-
cell autoreactivity to insulin has been equally observed in
diabetic and related non-diabetic individuals [33].
INTRATHYMIC DEVELOPMENT OF THE
DIABETOGENIC AUTOIMMUNE RESPONSE
Until recently, the question of a defect in the thymic
establishment of self-tolerance has not been intensively
investigated as a factor involved in the development of the
diabetogenic autoimmune response specifically directed
against insulin-secreting islet ß cells. However, data from
several studies add to the confirmation of this hypothesis.
Already in 1982, neonatal thymectomy was shown to prevent
the emergence of diabetes in an animal model of type 1
diabetes (T1D), the Bio-Breeding (BB) rat [34]. The
therapeutic benefit of thymectomy might in fact result from
the removal of a defective thymic censorship responsible for
a continuous release and enrichment of the peripheral T cell
pool with self-reactive T cell clones. In contrast, the
occurrence of diabetes is prevented by the transplantation of
thymus from diabetes-resistant (BBDR) to diabetes-prone
(BBDP) BB rats [35]. Thymus transplantation from NOD
mice to diabetes-resistant mouse strains was also shown to
induce autoimmune diabetes in the recipients [36]. Grafts of
pure thymic epithelium from NOD mouse embryos to
newborn C57BL/6 athymic mice induced CD4 and CD8 T
cell-mediated insulitis and sialitis [37]. At the histological
level, a defect in thymus tolerogenic function could result
from disorganization in the tissue environment such as the
presence of giant perivascular spaces as observed in the
NOD mouse thymus [38]. Epithelial defects have also been
characterized in the thymus of BB rats [39].
The development of the diabetogenic autoimmune
process may result from a defect in the establishment of
thymic central self-tolerance through abnormalities of
transcription or processing of ß cell-specific autoantigen-
encoding genes. Igf2 transcripts could not be found in the
thymus of more than 80% BBDP rats, in close accordance
with the incidence of diabetes in this BB rat strain (86%)
[40]. This gene defect was specific of the thymus since Igf2
mRNA was evidenced in brain and liver of BBDR rats. Two
independent groups have shown that the levels of INS
transcripts were low in the thymus from deceased fetuses
with genetic susceptibility to T1D (presence of VNTR class I
alleles), while they were higher in thymi from fetuses
bearing protective alleles (VNTR class III alleles) [41,42].
Another study has also reported low expression of insulin
within the thymus of NOD mice [43] while mice with
thymus-restricted insulin defect developed a strong
proinsulin-specific T cell reactivity [44]. Also, an
acceleration of autoimmune diabetes is observed in NOD
mice with drastically reduced Ins2 expression [45]. Thus
despite its low expression in the thymus, insulin also
contributes to central self-tolerance. It remains to be further
determined whether this contribution could be mediated
through the generation of insulin-specific T cells. With
regard to other ß cell autoantigens, it is interesting to note
that GAD67 is the dominant GAD isoform expressed in the
thymus whereas GAD65 is the autoantigen implicated in the
peripheral diabetogenic autoimmunity against ß cells [46].
The protein AIRE (AutoImmune Regulator) is a transcription
factor involved in the control of intrathymic expression of
“promiscuous” genes encoding peripheral autoantigens [47-
49]. Several mutations of the AIRE gene are responsible for
the development of autoimmune polyglandular syndrome
type 1 (APS-1) or APECED syndrome (Autoimmune
PolyEndocrinopathy, Candidiasis and Ectodermal Dystrophy).
AIRE expression is maximal in the thymus [50,51], and
thymus transplantation from Aire-/- mice to normal mice is
followed by the appearance of several autoimmune lesions in
grafted mice [52]. The profile of gene expression was
studied by microarrays in the thymus of Aire-/- mice, and
thymic levels of transcripts from several genes (including
Igf2, Ins2, Ot and neuropeptide Y) were severely decreased
in those thymi compared to normal ones [53].
PHARMACOLOGICAL PERSPECTIVES: THE
THYMUS AS A TARGET FOR A NOVEL TYPE OF
VACCINES
The study of neuroendocrine gene expression and
precursor processing in the thymus led to the identification
of thymic neuroendocrine self-antigens. With regard to
insulin-related gene expression in the thymus, IGF-2 — a
prominent fetal growth factor — was identified as the
dominant self-peptide precursor of the insulin family
expressed in the thymus epithelium from different species,
including man. This observation is in close accordance with
the theory of self-recognition, which, according to F.M.
Burnet, is not an inherited property but is gradually acquired
in the course of fetal life [54]. The tolerogenic properties of
thymic neuroendocrine self-peptides are already suspected
from what is known about the immunological tolerance of
classic hormones. The development of specific antibodies by
active immunization (i.e. experimental breakdown of self-
tolerance) revealed that OT is more tolerated than VP, and
that IGF-2 is also more tolerated than IGF-1, and much more
than insulin [32]. Some cases of diabetes insipidus arise from
an autoimmune process against VP-producing hypothalamic
neurons. Insulin is the primary autoantigen tackled by the
autoimmune process observed in T1D, and this might result
from its very low expression in the thymus. At the opposite,
autoimmunity has never been reported against OT and IGF-
2. The very strong tolerance of these peptides, resulting from
high expression of their genes in the thymus, may be
considered as the consequence of evolutionary pressure to
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protect from autoimmunity species reproduction and
individual ontogeny. In parallel with a physiological role of
the thymus in the establishment of central immune self-
tolerance, a thymus defective for this censorship of self-
reactivity more and more appears to exert a crucial influence
in the development of organ-specific autoimmunity. Already
in 1973, F.M. Burnet hypothesized and provided some
preliminary data supporting this novel concept according to
which the origin of autoimmunity resides in a defect in self-
tolerance setting (programming) during the process of T cell
differentiation within the thymus environment [55].
Consequently, an efficient and secure prevention and/or cure
of devastating autoimmune diseases such as T1D could be
based upon knowledge of the powerful tolerizing
mechanisms in the thymus. Such strategy may firstly rely on
the dominant IGF-2 derived thymic self-antigen(s) of the
insulin family. As previously said, insulin is poorly
expressed in the thymus and this fact may explain why
insulin — and insulin-derived epitopes — appears so
immunogenic in some experimental models [56, 57].
Similarly, insulin administered either orally or
subcutaneously does not exert any tolerogenic effect that
could protect the residual ß-cell mass from the destructive
autoimmune process [58-60].
On the basis of the hierarchy in the intrathymic
expression of insulin-related genes, we explore the
hypothesis that IGF-2 would be a more appropriate choice
for designing an antigen-driven tolerogenic approach in T1D
prevention. In this novel type of tolerogenic vaccination,
administration of self-peptide(s) derived from IGF-2 could
anergize or delete self-reactive T cells that have escaped the
central censorship because of a thymus dysfunction in the
establishment of ß-cell self-tolerance. Preliminary analyses
revealed that the major autoantigenic epitope of insulin
(sequence B9-23) and the homologous sequence B11-25 of
IGF-2 share the same affinity and equally compete for
binding to DQ8, a MHC class II allele conferring major
susceptibility to TID (Wûcherpfennig, personal communica-
tion). In a preclinical study, we investigated the cytokine
profile elicited by the DQ8 presentation of these sequences
to PBMCs isolated from ten T1D DQ8+ adolescents [61].
As shown in (Fig. 1), IGF-2 B:11-25 presentation is
associated with a regulatory/tolerogenic profile (high IL-10
and IL-10/IFN- g  ratio). These first data document the potent
tolerogenic and IL-10 inducing properties of an IGF-2 deriv-
Fig. (1). IL-10 and IFN- g  responses measured by Elispot assay in cultures of PBMCs isolated from DQ8+ T1D children and adolescents (6
females and 4 males; age range 7-16 years) treated with Ins B9-23 or IGF-2 B11-25 at two doses (10 and 50 µM). Mean ± SEM; N = 10; * P
< 0.05; ** P < 0.01 by Wilcoxon’s test.
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ed peptide and may explain why it is difficult to obtain
antibodies directed to IGF-2 at high titers after active
immunization with this protein. Therefore, with regard to
T1D prevention, administration of IGF-2 derived self-
antigen(s) constitutes an innovative approach that combines
antagonism with a dominant Ins autoantigen for binding to a
major susceptibility MHC-II allele, as well as promotion of a
specific antigen tolerogenic response. The complete design
of an efficient and safe tolerogenic vaccination procedure
could include self-antigen sequences derived from GAD67
and protein derived from alternatively spliced IA-2 that are
dominantly expressed in the thymus for presentation to pre-T
cells.
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